BWAY Brainsway Ltd. IFRS
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1505065
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY29.0%
TTM net income YoY169.6%
TTM EPS YoY138.5%
Revenue 3-yr CAGR11.4%
Net income 3-yr CAGR—
Margins
Gross margin74.6%
Operating margin3.4%
Net margin7.1%
FCF margin—
EBITDA margin5.0%
Returns
ROE5.6%
ROA3.7%
ROIC (approx.)9.8%
Asset turnover0.52x
Leverage & solvency
Liabilities / assets33.9%
Debt / equity0.00x
Current ratio5.19x
Interest coverage0.92x
Cash quality & payout
Operating cash flow / net income3.53x
Accruals ratio-9.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 | FY2020*2020-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $41.02M | $31.79M | $27.18M | $29.66M | $22.06M |
| Cost of revenue | $10.44M | $8.31M | $7.13M | $6.60M | $5.06M |
| Gross profit | $30.58M | $23.48M | $20.05M | $23.06M | $17.00M |
| R&D expense | $7.19M | $6.67M | $7.68M | $6.39M | $5.82M |
| SG&A expense | $5.80M | $5.32M | $6.85M | $5.78M | $4.72M |
| Operating income | $1.39M | -$4.96M | -$12.68M | -$5.00M | -$4.83M |
| Interest expense | $1.52M | $1.16M | $1.47M | -$1.68M | $319,000 |
| Pretax income | $3.46M | -$3.95M | -$13.03M | -$6.42M | -$5.15M |
| Income tax | $538,000 | $251,000 | $315,000 | $43,000 | $237,000 |
| Net income | $2.92M | -$4.20M | -$13.35M | -$6.46M | -$5.38M |
| EBITDA | $2.05M | -$4.60M | -$12.12M | -$4.44M | -$4.39M |
| EPS (basic) | 0.09 | -0.13 | -0.40 | -0.21 | -0.24 |
| EPS (diluted) | 0.05 | -0.13 | -0.40 | -0.21 | -0.24 |
| Balance sheet | |||||
| Cash & equivalents | $69.34M | $10.52M | $47.58M | $16.92M | $16.96M |
| Receivables | $4.60M | $3.78M | $4.84M | $6.33M | $5.58M |
| Inventory | $4.43M | $3.72M | $3.84M | — | — |
| Current assets | $79.67M | $55.47M | $58.09M | $65.45M | $24.30M |
| PP&E, netmay include right-of-use assets (IFRS) | — | — | — | — | $4.35M |
| Total assets | $94.32M | $62.97M | $64.48M | $75.73M | $34.01M |
| Current liabilities | $15.35M | $9.76M | $8.14M | $9.07M | $6.80M |
| Total liabilities | $32.00M | $21.39M | $19.08M | $18.41M | $14.38M |
| Shareholders' equity | $62.31M | $41.58M | $45.40M | $57.33M | $19.63M |
| Shares outstanding | 37.63M | 33.24M | 33.05M | 32.91M | 22.25M |
| Cash flow statement | |||||
| Operating cash flow | $10.30M | $1.28M | -$9.76M | $884,000 | -$1.44M |
| Capital expenditure | — | — | — | $2.24M | $2.47M |
| Free cash flow | — | — | — | -$1.35M | -$3.91M |
| Investing cash flow | $30.31M | -$37.41M | $42.17M | -$42.22M | -$2.46M |
| Financing cash flow | $18.26M | -$1.03M | -$1.55M | $41.52M | -$1.03M |
| Depreciation & amortization | $660,000 | $362,000 | $558,000 | $560,000 | $438,000 |
| Stock-based compensation | $1.44M | $381,000 | $1.47M | $1.89M | $799,000 |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.